January 14, 2018
For the fourth consecutive year, Greenberg Traurig, LLP’s Global Life Sciences & Medical Technology Group hosted two events coincident with the JP Morgan Healthcare Conference in San Francisco.
On Jan. 8, 2018, from 11:30 a.m. – 2 p.m., the Group presented “Insiders’ Views of Deal Making,” a lively and informative panel discussion that featured seasoned executives from leading life sciences companies. Speakers shared best practices, pitfalls of deals – including M&A, licensing, joint ventures, and strategic collaborations – and their predictions on what 2018 will hold for deal making. Panelists from the U.S., Europe and China included:
Shaun Grady, VP Strategic Partnering and Business Development, AstraZeneca
- Lizabeth Leveille, Associate VP and Head, Boston Innovation Hub; Business Development & Licensing, Merck Research Laboratories
- Jeremy Sohn, VP, Head of Digital Business Development & Licensing; Global Head of Digital Development, Novartis
- Angela Wang, Senior VP, Neusoft Corporation
- Qingxi (Charles) Wang, President, International Division, CSPC Pharmaceutical Group
The panel was moderated by the co-chairs of Greenberg Traurig’s Global Life Sciences & Medical Technology Group, David J. Dykeman (Boston shareholder, patent attorney and co-chair of Boston Intellectual Property & Technology Group) and David C. Peck (Fort Lauderdale shareholder, Corporate & Securities), as well as Fiona Adams (Corporate & Securities shareholder and co-chair of London office).
The program was followed by a private wine tasting and networking reception attended by more than 300 healthcare industry executives and investors.
About Greenberg Traurig’s Life Sciences & Medical Technology Group
Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational…